203 related articles for article (PubMed ID: 17761710)
1. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
[TBL] [Abstract][Full Text] [Related]
2. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
[TBL] [Abstract][Full Text] [Related]
3. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Coronel J; Cetina L; Pacheco I; Trejo-Becerril C; González-Fierro A; de la Cruz-Hernandez E; Perez-Cardenas E; Taja-Chayeb L; Arias-Bofill D; Candelaria M; Vidal S; Dueñas-González A
Med Oncol; 2011 Dec; 28 Suppl 1():S540-6. PubMed ID: 20931299
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
[TBL] [Abstract][Full Text] [Related]
6. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS).
Candelaria M; Burgos S; Ponce M; Espinoza R; Dueñas-Gonzalez A
Ann Hematol; 2017 Nov; 96(11):1825-1832. PubMed ID: 28831600
[TBL] [Abstract][Full Text] [Related]
7. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.
Espinoza-Zamora JR; Labardini-Méndez J; Sosa-Espinoza A; López-González C; Vieyra-García M; Candelaria M; Lozano-Zavaleta V; Toledano-Cuevas DV; Zapata-Canto N; Cervera E; Dueñas-González A
Expert Opin Investig Drugs; 2017 Apr; 26(4):481-487. PubMed ID: 28277033
[TBL] [Abstract][Full Text] [Related]
9. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
[TBL] [Abstract][Full Text] [Related]
11. Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
Hilakivi-Clarke L; Wärri A; Bouker KB; Zhang X; Cook KL; Jin L; Zwart A; Nguyen N; Hu R; Cruz MI; de Assis S; Wang X; Xuan J; Wang Y; Wehrenberg B; Clarke R
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27609189
[TBL] [Abstract][Full Text] [Related]
12. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Braiteh F; Soriano AO; Garcia-Manero G; Hong D; Johnson MM; Silva Lde P; Yang H; Alexander S; Wolff J; Kurzrock R
Clin Cancer Res; 2008 Oct; 14(19):6296-301. PubMed ID: 18829512
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
Chavez-Blanco A; Perez-Plasencia C; Perez-Cardenas E; Carrasco-Legleu C; Rangel-Lopez E; Segura-Pacheco B; Taja-Chayeb L; Trejo-Becerril C; Gonzalez-Fierro A; Candelaria M; Cabrera G; Duenas-Gonzalez A
Cancer Cell Int; 2006 Jan; 6():2. PubMed ID: 16448574
[TBL] [Abstract][Full Text] [Related]
17. Successful Use of Dose Dense Neoadjuvant Chemotherapy and Sodium Valproate with Minimal Toxicity in an Infant with Medulloblastoma in Extremely Poor General Condition.
Gupta A; Kumar A; Abrari A; Patir R; Vaishya S
World Neurosurg; 2016 Sep; 93():485.e1-5. PubMed ID: 27450977
[TBL] [Abstract][Full Text] [Related]
18. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Scherpereel A; Berghmans T; Lafitte JJ; Colinet B; Richez M; Bonduelle Y; Meert AP; Dhalluin X; Leclercq N; Paesmans M; Willems L; Sculier JP;
Eur Respir J; 2011 Jan; 37(1):129-35. PubMed ID: 20530048
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy and chemosensitization in solid malignancy.
Ronnekleiv-Kelly SM; Sharma A; Ahuja N
Cancer Treat Rev; 2017 Apr; 55():200-208. PubMed ID: 28431263
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy for solid tumors: from bench science to clinical trials.
Juo YY; Gong XJ; Mishra A; Cui X; Baylin SB; Azad NS; Ahuja N
Epigenomics; 2015; 7(2):215-35. PubMed ID: 25942532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
